Status:
UNKNOWN
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis
Lead Sponsor:
Assiut University
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
Brief Summary
Psoriasis is a chronic inflammatory and proliferative papulosquamous skin disease of unknown cause,overexpression of Anti Microbial Peptides is characteristic of psoriasis. Granulysin is a cytolytic ...
Detailed Description
The pathogenesis of psoriasis involves dynamic interactions between multiple cell types and numerous cytokines in response to triggers in genetically predisposed individuals leading to activation of T...
Eligibility Criteria
Inclusion
- Patients with clinically typical psoriatic lesions of different ages and sex.
- Patients with psoriasis vulgaris .
- Different degrees of severity according to Psoriasis Area and Index (PASI) Score
Exclusion
- Pregnant and lactating women.
- Patients received systemic medical treatment in the last one month.
- Patients with associated disease reported to increase the release of granulysin whether systemic e.g(infection, cancer, organ transplantation, autoimmune disease) or skin e.g( lichen planus , steven Johnson syndrome, toxic epidermal necrolysis, viral vesicles) and patients with severe immune deficiency treated by cell therapy.
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03469219
Start Date
July 1 2018
End Date
March 1 2019
Last Update
March 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt